Deep Track Capital’s Novavax NVAX Stock Holding History

Deep Track Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-998,542	Closed	-$6.29M	–	66
2025 Q2	$6.29M	Sell	998,542 -519,640	-34%	-$3.44M	0.2%	49
2025 Q1	$9.73M	Sell	1,518,182 -481,818	-24%	-$3.98M	0.32%	49
2024 Q4	$16.1M	Buy	+2,000,000	New	+$19.3M	0.6%	41
2023 Q4	–	Sell	-1,000,000	Closed	-$7.24M	–	73
2023 Q3	$7.24M	Buy	+1,000,000	New	+$7.99M	0.28%	55

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deep Track Capital's NVAX Position: Q3 2025 in Review

Deep Track Capital sold out of Novavax (NVAX) in Q3 2025, closing a stake of 998,542 shares — an estimated $6.29M sold.

Deep Track Capital first reported a position in NVAX in Q3 2023 and held it in 4 quarters. The position peaked at $16.1M in Q4 2024. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

Deep Track Capital reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
Deep Track Capital sold 998,542 Novavax shares in Q3 2025, an estimated $6.29M.
Deep Track Capital first reported a position in Novavax in Q3 2023 and held it in 4 quarters.
Deep Track Capital's Novavax position peaked at $16.1M in Q4 2024.
249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on Deep Track Capital's 13F filing for Q3 2025, filed 14 Nov 2025.